OverviewSuggest Edit

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
TypePublic
Founded2008
HQSouth San Francisco, CA, US
Websitecytomx.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)158(+16%)
Job Openings29
Revenue (FY, 2020)$100.4 M(+75%)
Share Price (Mar 2021)$7.4(-2%)
Cybersecurity ratingAMore

Key People/Management at CytomX Therapeutics

Sean A. McCarthy

Sean A. McCarthy

President, Chief Executive Officer and Chairman
Amy C. Peterson

Amy C. Peterson

EVP, Chief Development Officer
Carlos Campoy

Carlos Campoy

SVP, Chief Financial Officer
Alison Joly

Alison Joly

SVP, Program and Alliance Management
W. Michael Kavanaugh

W. Michael Kavanaugh

SVP, Chief Scientific Officer, Head of Research and Non-Clinical Development
Charles S. Fuchs

Charles S. Fuchs

Director
Show more

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
151 Oyster Point Blvd #400
Show all (1)

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Revenue

CytomX Therapeutics's revenue was reported to be $100.36 m in FY, 2020
USD

Revenue (FY, 2020)

100.4m

Net income (FY, 2020)

(32.9m)

EBIT (FY, 2020)

(48.6m)

Market capitalization (30-Mar-2021)

479.4m

Closing stock price (30-Mar-2021)

7.4

Cash (31-Dec-2020)

191.9m

EV

312.4m
CytomX Therapeutics's current market capitalization is $479.4 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

7.7m15.0m71.6m59.5m57.5m100.4m

Revenue growth, %

95%

General and administrative expense

12.6m19.9m25.6m33.5m36.8m36.0m

R&D expense

28.4m54.8m92.3m103.9m131.6m112.9m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.9m2.2m3.1m3.5m11.7m8.8m24.1m14.2m21.3m12.5m29.5m9.0m10.7m49.6m16.6m17.8m

General and administrative expense

4.1m5.0m4.6m5.0m5.7m6.0m6.2m7.4m9.0m8.1m9.7m9.4m8.5m9.6m8.7m8.6m

R&D expense

9.2m13.4m12.7m13.3m14.6m28.1m28.9m22.5m25.6m27.5m36.4m30.8m28.0m42.8m24.1m24.0m

Operating expense total

13.2m18.4m17.4m18.4m20.3m34.1m35.2m29.8m34.6m35.7m46.1m40.2m36.4m52.4m32.7m32.7m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

59.8m104.6m177.5m247.6m188.4m191.9m

Accounts Receivable

744.0k2.2m10.1m97.0k13.0k798.0k

Prepaid Expenses

4.4m9.3m7.2m7.1m

Inventories

2.3m3.9m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(35.4m)(58.9m)(43.1m)(84.6m)(102.2m)(32.9m)

Depreciation and Amortization

1.2m1.7m1.6m1.9m146.0k146.0k

Accounts Payable

2.9m1.8m(2.4m)261.0k(374.0k)(857.0k)

Cash From Operating Activities

(27.4m)(2.0m)170.4m(75.5m)(140.5m)5.3m
USDQ3, 2015

Financial Leverage

-1.2 x
Show all financial metrics

CytomX Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

4

Patents (US)

13

Patents Pending

144

Phase I Trials Products

1
Show all operating metrics

CytomX Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

CytomX Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

CytomX Therapeutics Online and Social Media Presence

Embed Graph

CytomX Therapeutics News and Updates

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform…

Thinking about buying stock in Ion Geophysical, OncoCyte, electroCore, CytomX Therapeutics, or Catalyst Biosciences?

NEW YORK, March 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, OCX, ECOR, CTMX, and CBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody® technology platform, to…

CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody® technology platform, tod…

UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has issued and sold an additional 2…

Steven Cohen Snaps Up Stake In CytomX Therapeutics

Guru invests in biotech focusing on cancer treatments
Show more

CytomX Therapeutics Blogs

Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity Preclinical characterization of a dual-masked IFNα-2b

Erwan Le Scolan, Ph.D. Presented at the Cytokine-Based Cancer Immunotherapies Summit, March 24th, 2021.

CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

-Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in breast cancer- -Enrollment continues in Phase 2 expansion study of CX-2029 in four cancer types, in partnership with AbbVie- -Bristol Myers Squibb expands anti-CTLA-4 Probody Program

CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day

CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day Content Import Thu, 02/04/2021 - 08:02 CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day February 4, 2021 at 8:00 AM EST This release is a backfill fr…

CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares kevindavis Wed, 02/03/2021 - 08:19 CytomX Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares February 3, 2021 at 8:18 AM EST …

CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients with Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

Melissa Johnson, Jordi Rodon Ahnert, Nehal Lakhani, Rachel E. Sanborn, Anthony El-Khoueiry, Navid Hafez, Hirva Mamdani, Valentina Boni, Henry Castro, Alison L. Hannah, Alexander Spira. Presented at the IASLC 2020 World Conference on Lung Cancer Singapore virtual meeting, January 28-31, 2021.

Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of the Probody® Therapeutic (Pb-Tx) Praluzatamab Ravtansine (CX-2009) in Metastatic HR-Positive/HER2-Negative Breast Cancer (mHR+/HER2− BC) and of CX-2009 as Monotherapy and in Combination Therapy With Pacmilimab (CX-072) in Metastatic Triple-Negative Breast Cancer (TNBC)

Kathy D. Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison Hannah, Valentina Boni. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.
Show more

CytomX Therapeutics Frequently Asked Questions

  • When was CytomX Therapeutics founded?

    CytomX Therapeutics was founded in 2008.

  • Who are CytomX Therapeutics key executives?

    CytomX Therapeutics's key executives are Sean A. McCarthy, Amy C. Peterson and Carlos Campoy.

  • How many employees does CytomX Therapeutics have?

    CytomX Therapeutics has 158 employees.

  • What is CytomX Therapeutics revenue?

    Latest CytomX Therapeutics annual revenue is $100.4 m.

  • What is CytomX Therapeutics revenue per employee?

    Latest CytomX Therapeutics revenue per employee is $635.2 k.

  • Who are CytomX Therapeutics competitors?

    Competitors of CytomX Therapeutics include Stingray Therapeutics, Forbius and SQZ Biotech.

  • Where is CytomX Therapeutics headquarters?

    CytomX Therapeutics headquarters is located at 151 Oyster Point Blvd #400, South San Francisco.

  • Where are CytomX Therapeutics offices?

    CytomX Therapeutics has an office in South San Francisco.

  • How many offices does CytomX Therapeutics have?

    CytomX Therapeutics has 1 office.